Basics Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases. IPO Date: October 23, 2013 Sector: Healthcare Industry: Biotech Market Cap: $577.71M Activated in VL: True Average Daily Range Avg Daily Range: $0.48 | 3.12% Avg Daily Range (30 D): $0.10 | 4.02% Avg Daily Range (90 D): $0.12 | 3.57% Institutional Daily Volume Avg Daily Volume: 3.07M Avg Daily Volume (30 D): 14.33M Avg Daily Volume (90 D): 10.72M Trade Size Avg Trade Size (Sh.): 148 Avg Trade Size (Sh.) (30 D): 431 Avg Trade Size (Sh.) (90 D): 304 Institutional Trades Total Inst.Trades: 5,191 Avg Inst. Trade: $2.56M Avg Inst. Trade (30 D): $1.84M Avg Inst. Trade (90 D): $2.04M Avg Inst. Trade Volume: .21M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.12M Avg Closing Trade (30 D): $2.03M Avg Closing Trade (90 D): $2.76M Avg Closing Volume: 354.17K         News Jun 2, 2025 @ 4:00 PM Scott+Scott Attorneys at Law LLP Continues to Remi... Source: Scott+Scott Attorneys At Law Llp Jun 2, 2025 @ 1:05 PM IOVA Investors Have Opportunity to Lead Iovance Bi... Source: Prnewswire Jun 1, 2025 @ 9:41 PM ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourage... Source: N/A May 31, 2025 @ 11:08 AM IOVA CLASS NOTICE: Iovance Biotherapeutics, Inc. I... Source: N/A May 29, 2025 @ 4:00 PM Iovance Biotherapeutics, Inc. (IOVA) Investors Who... Source: Prnewswire Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.36 $-.28 $-.34 Diluted EPS $-.36 $-.28 $-.34 Revenue $ 49.32M $ 58.56M $ 31.11M Gross Profit $ -.42M $ 18.73M $ -.26M Net Income / Loss $ -116.16M $ -83.54M $ -97.1M Operating Income / Loss $ -121.22M $ -89.07M $ -101.91M Cost of Revenue $ 49.74M $ 39.82M $ 31.37M Net Cash Flow $ 56M $ -64.57M $ 94.49M PE Ratio     Splits Sep 26, 2013:   1:100 Apr 06, 2010:   24:1